Reforgene ranks in Guangzhou's 2024 Top 10 science and technology leaders
Recently, the Guangzhou Financial Development Service Center released the list of selected enterprises and institutions for the 2024 Guangzhou pre-IPO "Bellwether" enterprises and outstanding private equity investment institutions. Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene"), on the strength of its outstanding overall capabilities and strong scientific and technological innovation capacity, was successfully selected into the "2024 Guangzhou Top 10 Strongest Science and Technology Bellwethers". The list is guided by the Office of the Financial Committee of the CPC Guangzhou Municipal Committee, and jointly evaluated by the Guangzhou Financial Development Service Center together with ICBC Guangzhou Branch, Postal Savings Bank of China Guangzhou Branch, GF Securities Co., Ltd., Guangdong Equity Exchange Center and venture capital institutions from the Guangdong-Hong Kong-Macao Greater Bay Area, aiming to consolidate and enhance the "Bellwether" brand of high-quality corporate listings, vigorously develop new quality productive forces, cultivate new quality listed companies through multiple measures, strengthen private equity investment to support the growth of Guangzhou enterprises, and identify and cultivate a group of pre-IPO enterprises with "Bellwether" attributes.
Reforgene is a leading innovative gene editing drug company in China, driven by gene editing technology and dedicated to bringing novel medicines to life. Since its establishment, the company has upheld the spirit of innovation, adhered to the dual-drive strategy of breakthroughs in underlying gene editing technology and innovative drug R&D, continuously improved its core competitiveness, and provided global patients with first-in-class and best-in-class innovative medicines. This selection into the Guangzhou Top 10 Strongest Science and Technology Bellwethers is not only recognition of Reforgene's overall strength, but also affirmation of its sustained innovation and pursuit of excellence.
This award is both an honor and an encouragement. In future development, Reforgene will always take innovation as its foundation, deepen its presence in the gene editing medicine field, continuously enhance its innovation capability and market competitiveness, strive to grow into an innovative drug company with global influence, and bring cutting-edge biotechnology to the benefit of human health.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.